Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 7/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 4/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412012 | 0.83 | RAB9A (0.41) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL5421407 | 0.83 | RAB9A (0.41) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL5513715 | 0.83 | RAB9A (0.41) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL6415401 | 0.78 | REN (0.42) | SMN1; SMN2MAPT | |
| SCHEMBL7559455 | 0.76 | DGAT1 (0.40) | TP53RAB9ACTSKPTPN2PTPN1 | |
| SCHEMBL5736600 | 0.76 | NPC1 (0.42) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL5736602 | 0.76 | NPC1 (0.42) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL5729158 | 0.74 | CTSK (0.43) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL5729161 | 0.74 | CTSK (0.43) | NPC1TP53RAB9ASMN1; SMN2CTSK | |
| SCHEMBL5947390 | 0.74 | RAB9A (0.40) | NPC1TP53RAB9ASMN1; SMN2KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288336-A1 | Cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288336-A1 | Cysteine protease inhibitors | CTSF, CTSS, CTSB | NPC1 246/4885TP53 807/4885RAB9A 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.